News on GlaxoSmithKline (Ticker: GSK) continually updated from thousands of sources around the net.
Midway through the third quarter of 2014, the Pharmaceutical-Biotech Industry is busy finishing an impressive array of capital construction projects.
POZEN Inc. , a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the acquisition of all of GlaxoSmithKline's rights to TreximetA have been acquired by Pernix Therapeutics Holdings, Inc. .
GlaxoSmithKline plc today announced that the FDA has approved Arnuitya ElliptaA , a once-daily inhaled corticosteroid medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older.
But is this merely a buying opportunity for a solid company? It trades as one of the cheapest pharma companies around and offers one of the best dividend yields.
U.S. generic drugs company Mylan Inc., private equity groups TPG Capital LLP, Advent International, KKR & Co L.P., and Warburg Pincus LLC, and some Indian drug makers have made it through to the second round of bidding for a portfolio of mature drugs being sold by GlaxoSmithKline PLC, according to people familiar with the sales process.
Dividends: They're the cornerstone to any healthy, long-term-focused portfolio. But when it comes to the health care industry, securing dividend income isn't as easy as it sounds.
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Sanford-Burnham Medical Research Institute on Aug. 19 announced it has selected Dr. Perry Nisen as CEO at its La Jolla, Calif.-based headquarters.
According to GuruFocus list of 52-week lows , these Guru stocks have reached their 52-week lows.
With the death toll in the worst Ebola outbreak in history exceeding 1,000, pharmaceutical companies and health authorities are sprinting to develop new drugs and vaccines.
Turnover of GlaxoSmithKline was US$44 billion in 2013 and it annually spends $6.5 billion in R&D.
It's a debate federal regulators and drug companies have all the time. Should a company with an experimental drug give it to people in need to potentially save their lives, or should regulators make sure the drug is safe before it does any more harm? It's a question that seems to always result in a lose-lose situation.
There's a good chance that the vast majority of people who receive it won't derive any benefits whatsoever.
By now, most investors know all the problems facing pharmaceutical giant GlaxoSmithKline .
Updated: Thu Aug 21, 2014 01:39 am
Copyright © 2014 Topix LLC